{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:21:24Z","timestamp":1769149284210,"version":"3.49.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.critrevonc.2019.06.009","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T12:26:08Z","timestamp":1561638368000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Primary central nervous system lymphoma: Novel precision therapies"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-3757","authenticated-orcid":false,"given":"Patrizia","family":"Mondello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-5996","authenticated-orcid":false,"given":"Michael","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-8983","authenticated-orcid":false,"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.06.009_bib0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR t cells in CNS diffuse Large-B-Cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOH.0b013e3282f3deaa","article-title":"Exploiting the mammalian target of rapamycin pathway in hematologic malignancies","volume":"15","author":"Altman","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0025","first-page":"129","article-title":"Radioprotective effects of quercetin and ethanolic extract of Propolis in gamma-irradiated mice","volume":"60","author":"Benkovi\u0107","year":"2009","journal-title":"Arch. Ind. Hyg. Toxicol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0030","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0040","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","author":"Camilleri-Bro\u00ebt","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0045","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0050","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0055","first-page":"128","article-title":"Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network","author":"Choquet","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.critrevonc.2017.03.019","article-title":"Primary central nervous system lymphoma","volume":"113","author":"Citterio","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse Large-B-Cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0070","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/01.WNL.0000109673.75316.D8","article-title":"Cognitive functions in survivors of primary central nervous system lymphoma","volume":"62","author":"Correa","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0075","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway As drug target in human Cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0080","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0085","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0090","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0095","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2010-04-281170","article-title":"Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia","volume":"117","author":"Fiedler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0100","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/neuonc\/nor107","article-title":"Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas","volume":"13","author":"Fischer","year":"2011","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0105","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","article-title":"Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly","volume":"22","author":"Fritsch","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0110","author":"Ghesquieres","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0115","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/NEN.0000000000000076","article-title":"CNS lymphoma: a practical diagnostic approach","volume":"73","author":"Giannini","year":"2014","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0120","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0125","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0130","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ccell.2017.05.004","article-title":"Ibrutinib in PCNSL: the curious cases of clinical responses and aspergillosis","volume":"31","author":"Grommes","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0135","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013Modified t cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0140","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0145","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/cncr.30965","article-title":"Diagnosis and management of primary central nervous system lymphoma","volume":"123","author":"Han","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0150","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0155","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.05.010","article-title":"Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: review of literature and future opportunities","volume":"127","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","article-title":"High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma","volume":"83","author":"Holdhoff","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0170","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1200\/jco.2014.32.15_suppl.2079","article-title":"Lenalidomide in the treatment of relapsed primary central nervous system lymphoma (PCNSL)","volume":"32","author":"Houillier","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0175","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1078-0432.CCR-13-0474","article-title":"Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma","volume":"20","author":"Kadoch","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0180","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1038\/bcj.2014.87","article-title":"Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations","volume":"4","author":"Kersten","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0185","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2015-11-684183","article-title":"B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice","volume":"127","author":"Knittel","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0190","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0195","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II trial of temsirolimus for Relapsed\/Refractory primary CNS lymphoma","volume":"34","author":"Korfel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0200","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0205","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0210","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0215","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0220","doi-asserted-by":"crossref","first-page":"e14036","DOI":"10.1200\/JCO.2018.36.15_suppl.e14036","article-title":"Lenalidomide as treatment for relapsed or refractory primary CNS lymphoma: a single institutional experience","volume":"36","author":"Molaie","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0225","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1634\/theoncologist.2016-0103","article-title":"Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?","volume":"21","author":"Mondello","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0230","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00401-010-0709-7","article-title":"Mutations of CARD11 but not TNFAIP3 may activate the NF-\u03baB pathway in primary CNS lymphoma","volume":"120","author":"Montesinos-Rongen","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0235","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0240","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0245","first-page":"287","article-title":"X-linked agammaglobulinemia. A clinical and molecular analysis","volume":"75","author":"Ochs","year":"1996","journal-title":"Bull. Sch. Med. Md"},{"issue":"Suppl 4","key":"10.1016\/j.critrevonc.2019.06.009_bib0250","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0255","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0260","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008201717089","article-title":"Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature","volume":"8","author":"Reni","year":"1997","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0265","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0270","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2005-03-0897","article-title":"Gene expression and angiotropism in primary CNS lymphoma","volume":"107","author":"Rubenstein","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0275","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0280","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0285","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood-2012-07-440974","article-title":"Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma","volume":"121","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0290","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/blood-2013-01-476333","article-title":"CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma","volume":"121","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0295","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0300","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0305","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin\u2019s lymphoma subtypes: the University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0310","series-title":"World Health Organization","author":"Swerdlow","year":"2019"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0315","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/861060","article-title":"Lenalidomide in diffuse large B-cell lymphoma","volume":"2012","author":"Thieblemont","year":"2012","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0320","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0325","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15787","article-title":"Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma","author":"Vu","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0330","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1158\/1078-0432.CCR-11-0625","article-title":"Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI","volume":"18","author":"Wieduwilt","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0335","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0345","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0350","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2019.06.009_bib0355","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br. J. Haematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819301283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819301283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:33:29Z","timestamp":1760902409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842819301283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":71,"alternative-id":["S1040842819301283"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.06.009","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary central nervous system lymphoma: Novel precision therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}